Fair question.
Full text of article is available:
https://www.researchgate.net/figure/Models-of-payment-for-the-participation-of-research-subjects_tbl1_7737793
I searched my journal databases and there are just as many articles stating there are numerous disadvantages associated with payment of subjects. Payment is not common practice in Australia; more common in the US. Regardless, payment in Imagion's trial would require a fairly significant trial re-design...
Should we petition Red Cross to enable payment for plasma donations, and the sprog clinics to pay sperm donors also?
- Forums
- ASX - By Stock
- IBX
- Financial incentives for recruiting is not uncommon
Financial incentives for recruiting is not uncommon
-
-
Share
I think it's going to be really hard to get a 15 patient cohort without a trial redesign.
And then what about the next step, 300 people? You can understand the markets apprehension.
- There are more pages in this discussion • 13 more messages in this thread...
Featured News
Add IBX (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.415M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
IBX (ASX) Chart |
Day chart unavailable